scholarly journals Respiratory Volume Monitoring Reduces Hypoventilation and Apnea in Subjects Undergoing Procedural Sedation

2017 ◽  
Vol 63 (4) ◽  
pp. 448-454 ◽  
Author(s):  
Robert H Nichols ◽  
Justin A Blinn ◽  
Thuan M Ho ◽  
Robert A McQuitty ◽  
Michael P Kinsky
Keyword(s):  
Procedural Sedation ◽  
Respiratory Volume

Improving patient safety during procedural sedation via respiratory volume monitoring: A randomized controlled trial

2018 ◽  
Vol 46 ◽  
pp. 118-123 ◽  
Author(s):  
Donald M. Mathews ◽  
Michael J. Oberding ◽  
Eric L. Simmons ◽  
Stephen E. O'Donnell ◽  
Kevin R. Abnet ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Patient Safety ◽  
Controlled Trial ◽  
Procedural Sedation ◽  
Respiratory Volume ◽  
Randomized Controlled

Remimazolam: A Novel Option for Procedural Sedation in High Risk Patients

2021 ◽  
pp. 089719002110273
Author(s):  
Megan M. Pantos ◽  
Daniel R. Kennedy ◽  
Eric C. Nemec
Keyword(s):  
Drug Interactions ◽  
The Elderly ◽  
Volume Of Distribution ◽  
Procedural Sedation ◽  
Dose Titration ◽  
Onset Of Action ◽  
Elimination Half ◽  
Risk Patients ◽  
Require Dose ◽  
Drug Review

Purpose: The purpose of this drug review was to explore the safety and efficacy of the newly approved benzodiazepine, remimazolam, in order to evaluate its place in therapy. Summary: Remimazolam has a faster onset of action and recovery time than midazolam when given as single IV doses. Additionally, it has no known CYP450 interactions that would contribute to drug-drug interactions. Patients with severe hepatic impairment may require dose titration as well as the elderly who should be closely monitored. Although remimazolam vials should be protected from light and must be reconstituted immediately before use, the reconstituted vial may be stored for later use at room temperature for up to 8 hours. Remimazolam is more expensive than current options used in practice, as such individual institutional formulary and provider preference will require review to see if its advantages are worth the additional cost and to determine its place in therapy. Conclusion: Remimazolam is a novel option when choosing a benzodiazepine for procedural sedation that has pharmacokinetic and pharmacodynamic advantages when compared to other commonly prescribed sedatives. Remimazolam has proved superior to midazolam when analyzing drug-drug interactions, onset, and time to alertness. Remimazolam also has a shorter elimination half-life and decreased volume of distribution when compared to midazolam.

Impact of young age on outcomes of emergency department procedural sedation

2021 ◽  
Vol 46 ◽  
pp. 116-120
Author(s):  
Michael Schlegelmilch ◽  
Mark G. Roback ◽  
Maala Bhatt ◽  
David W. Johnson ◽  
Ken J. Farion ◽  
...  
Keyword(s):  
Emergency Department ◽  
Young Age ◽  
Procedural Sedation

Remimazolam: A Review in Procedural Sedation

Drugs ◽  
2021 ◽  
Author(s):  
Arnold Lee ◽  
Matt Shirley
Keyword(s):  
Procedural Sedation
Sign in / Sign up

Export Citation Format

Share Document